Heat resistant RNA polymerases
By using the heat-resistant RNA polymerase phiFa_44 of the bacteriophage phiFa to perform transcription reaction at high temperature, the problem of inactivation of existing RNA polymerases at high temperatures is solved, and the transcription efficiency and sensitivity of nucleic acid detection are improved.
Patent Information
- Application Number
- CN202380026471.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-20
- Filing Date
- 2023-01-20
- Publication Date
- 2024-11-15
AI Technical Summary
The existing RNA polymerases are inactivated after incubation at 65°C for more than 5 minutes, making it difficult to maintain activity at high temperatures, limiting the efficiency of in vitro transcription and diagnostic methods.
Thermal resistance DNA-dependent RNA polymerase phiFa_44 from the bacteriophage phiFa was used to improve the stability of RNA polymerase by conducting transcription reactions at a temperature between 30°C and incubating in a buffer containing NaCl. and activity.
Thermal resistance transcription reaction that maintains RNA polymerase activity at high temperature is achieved, which improves in vitro transcription efficiency and supports nucleic acid detection strategies performed at high temperatures, such as LAMP amplification and detection of CRISPR-Cas system.
Smart Images

Figure BDA0005034408520000181 
Figure BDA0005034408520000191 
Figure BDA0005034408520000201
Abstract
Description
Technical Field
[0001] The present invention relates to novel thermostable RNA polymerases and their use in in vitro transcription and in diagnostic methods. Background Art
[0002] In vitro transcription (IVT) reactions generally require a template nucleic acid molecule including a promoter, ribonucleotide triphosphates, a buffer system containing DTT and magnesium ions, and a suitable ribonucleic acid (RNA) polymerase. The RNA polymerase is generally selected from single-subunit bacteriophage-derived RNA polymerases, such as SP6, T3, and T7. Transcription begins with the binding of the RNA polymerase to its promoter sequence, and then the template chain enters the active site, produces RNA transcripts, and terminates the transcription reaction.
[0003] In addition to being used in IVT, RNA polymerases are commonly used in nucleic acid amplification methods, particularly for diagnostic purposes. For example, nucleic acid sequence-based amplification (NASBA; US5654142A) and transcription-mediated amplification (TMA; WO1991001384A1) involve alternating cycles in which RNA polymerase and reverse transcriptase continuously generate each other's templates under isothermal conditions. After amplification, hybridization of complementary oligonucleotide probes can be detected by a detectable label, such as that used in quantitative PCR (also known as quantitative real-time PCR). In addition, certain nucleic acid detection systems based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) proteins utilize RNA intermediates (Steens et al., 2021, Nature Comm 12: 1-12).
[0004] It would be advantageous if the reaction temperature could be increased to increase the reaction rate. For example, if the reaction temperature of isothermal amplification is increased, RNA with secondary structure may be amplified. However, although RNA polymerase variants that exhibit higher thermal stability than wild-type phage-derived RNA polymerase have been identified (Boulain et al., 2013, Protein Eng Des Sel, 26(11): 725-734), no commercially available RNA polymerases remain active after incubation at 65°C for more than 5 minutes.
[0005] Therefore, there is a need for RNA polymerases with improved stability and activity at higher reaction temperatures. Summary of the invention
[0006] The present invention provides a method, comprising: incubating a template nucleic acid molecule with a protein having at least 50% sequence identity with SEQ ID NO: 1 in the presence of ribonucleic acid nucleotides (rNTR) and a suitable buffer; and transcribing at least part of the template nucleic acid molecule into an RNA molecule by performing a transcription reaction at a temperature between 30°C and 80°C. The template nucleic acid molecule is preferably a deoxyribonucleic acid (DNA) template molecule, which is a single-stranded or double-stranded DNA template molecule. The buffer preferably includes 25mM to 200mM NaCl. The transcription reaction is preferably performed at a temperature of 45°C to 75°C. The template nucleic acid molecule can be generated by any means including a pre-amplification reaction.
[0007] The transcribed RNA molecules can be further incubated with a nucleic acid detection system based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) proteins. The CRISPR-Cas nucleic acid detection system preferably includes: a) an effector complex including a type III Cas protein and at least one CRISPR RNA (crRNA) bound to a target RNA molecule; b) a device for directly or indirectly determining the level of cyclic oligoadenylic acid (cOA). In a preferred method of the present invention, the preamplification reaction, the transcription reaction, and the incubation with the nucleic acid detection system are all performed in a one-pot reaction.
[0008] The present invention further provides a protein having at least 50% sequence identity to SEQ ID NO: 1. The protein preferably includes a suitable tag.
[0009] The present invention further provides a nucleic acid molecule encoding a protein of the present invention. The nucleic acid molecule is preferably codon-optimized to express the protein in a suitable host cell.
[0010] The present invention further provides a host cell for expressing the protein of the present invention.
[0011] The present invention further provides the use of the protein of the present invention in performing a transcription reaction to transcribe at least part of a template nucleic acid molecule into an RNA molecule. The transcription reaction is preferably performed at a temperature between 30°C and 80°C, preferably at a temperature between 45°C and 75°C. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 : Substrate specificity of PhiFa_44 for IVT. The marker used was NEB low range ssRNA (NEB #N0364S).
[0013] Figure 2:Analysis of phiPa_44IVT performance under different NaCl concentrations and temperatures. A: Template only, no DNase. B: Template only, with DNase. C: PhiFa only, with DNase.
[0014] Figure 3 : SARS-COV-2 one-pot reaction.
[0015] Figure 4 : In vitro transcription reactions using single-stranded (ss) DNA templates A and B. "+" indicates the presence, while "-" indicates the absence of phiFa protein.
[0016] Figure 5 : In vitro PhiFa-44 RNA transcription assay using 5' fluorescently labeled (Cy3) single-stranded DNA (50 nucleotides) as template. One reaction was subjected to RNase H treatment. All products were analyzed in native 4-20% (w / v) polyacrylamide gels. Fluorescent gel scanning was used to selectively visualize nucleic acids. Cy3 filters only show Cy3-labeled reaction products (left), while SYBR Gold staining and subsequent visualization through Cy2 filters shows all nucleic acids (right). DETAILED DESCRIPTION
[0017] definition
[0018] The term "phiFa_44" as used herein refers to a protein having SEQ ID NO: 1. The protein is derived from bacteriophage phiFa (GenBank: MH673672.2; Taxonomy ID: 1400796), which was isolated near Mount Etna in Sicily, Italy (Severinov et al., 2014, Bacteriophage 4: e29399, DOI: 10.4161 / bact.29399).
[0019] The term "RNA polymerase" as used herein in connection with phiFa_44 refers to a DNA-dependent RNA polymerase that catalyzes the synthesis of a complementary RNA strand from a DNA template.
[0020] The term "promoter" as used herein refers to a nucleotide sequence at the 5' end of a gene to which the transcription initiation machinery (including RNA polymerase, such as DNA-dependent RNA polymerase) binds and initiates transcription, and is usually located 5-100 bp upstream of the start codon of the gene.
[0021] The term "clustered regularly interspaced short palindromic repeats (CRISPR)" as used herein refers to one or more specific regions of DNA in the genome of a prokaryotic microorganism. These regions are characterized by the presence of nucleotide repeats interspersed by spacer sequences, typically direct DNA repeats of 25- to 38 bp, separated by unique spacer sequences of similar length (Grissa et al., 2007, BMC Bioinformatics 8: 172), which are derived from previous contact with invaders. They act as memory and quickly attack these invaders at the next infection. The genomic region contains one or more genes encoding CRISPR-associated (Cas) effector proteins located near the CRISPR locus.
[0022] As used herein, the term "CRISPR RNA or crRNA" refers to an RNA molecule derived from CRISPR that includes a spacer sequence and at least a 5' repeat sequence-derived end. The crRNA preferably has a length of at least 30 nucleotides, more preferably at least 34 nucleotides, more preferably at least 40 nucleotides, and more preferably at least 46 nucleotides. The crRNA is preferably less than 1000 nucleotides, preferably less than 200 nucleotides, and preferably less than 100 nucleotides. The crRNA molecule may contain ribonucleic acid nucleotide analogs, such as ribonucleotides and deoxyribonucleotides based on inosine, uridine, xanthine, hypoxanthine, 2,6-diaminopurine and 6,8-diaminopurine.
[0023] The term "CRISPR-associated (Cas) effector protein" as used herein refers to a protein associated with crRNA. CRISPR / Cas systems are currently divided into two categories. Class 1 systems utilize multi-subunit Cas complexes, while Class 2 systems use single Cas proteins to regulate their activity. Class 1, Type III CRISPR-Cas systems have been developed to specifically target RNA sequences. The unique proteins in these systems are: Cas3 in Class 1, Type I systems; Cas9 in Class 2, Type II systems; Cas10 in Class 1, Type III systems; Cas12 in Class 2, Type V systems; and Cas13 in Class 2, Type VI systems.
[0024] As used herein, the term "effector complex" refers to a CRISPR-Cas ribonucleoprotein complex that has (ribo) nuclease activity and can cut and inactivate invading nucleic acid sequences, wherein the invading nucleic acid sequence includes a complementary sequence to the spacer sequence in the crRNA. The complex includes at least one crRNA and at least one Cas effector protein.
[0025] The term "reverse transcription" as used herein refers to the production of complementary DNA (cDNA) from an RNA template. Retroviruses and some retrotransposons encode an enzyme known as a reverse transcriptase to replicate their genomes. Retroviral reverse transcriptases have three sequential biochemical activities: RNA-dependent DNA polymerase activity, ribonuclease H (RNAse H) activity, and DNA-dependent DNA polymerase activity. Enzymes commonly used for reverse transcription of RNA are Moloney murine leukemia virus reverse transcriptase and avian myeloblastosis virus reverse transcriptase and variants thereof, including thermostable variants.
[0026] The term "isothermal amplification" as used herein refers to exponential amplification of nucleic acid molecules without thermal cycling required for polymerase chain reaction (PCR). In isothermal methods, polymerases with strand displacement activity are generally used. Preferably, the isothermal reaction of a single tube includes nucleic acid sequence-based amplification (NASBA), loop-mediated isothermal amplification (LAMP), helicase-dependent amplification (HDA), recombinase polymerase amplification (RPA) reaction and nicking enzyme amplification reaction (NEAR). Preferably, the isothermal reaction of a single tube is loop-mediated isothermal amplification (LAMP).
[0027] The term "V-type effector protein", as used herein, refers to 2 types of effector proteins, characterized by a specific nuclease domain required for cleaving non-target DNA molecules. At least 13 subtypes are currently known: VA, VB to VM. V-type Cas proteins can be isolated from Francisella novicida, Acidaminococcus sp., Lachnospiraceae sp., Prevotella sp., and some archaea. The total guide length is preferably 42-44 nucleotides. The gRNA of the Cas12 V-type effector protein preferably includes a dinucleotide TT as a protospacer adjacent motif (PAM) in the gRNA, more preferably a 5'-TTTN motif. Exemplary V-type effector proteins are Cpf1 (VA type) and C2c1 (VB type). Cas12 and Cas14 are prototype V-type effector proteins.
[0028] The term "type VI effector protein" as used herein refers to 2 types of effector proteins with non-specific RNase activity. There are currently 4 known subtypes: subtypes VI-A, VI-B, VI-C and VI-D. Type VI Cas proteins can be isolated from organisms such as Leptotrichia buccalis, Leptotrichia shahii, Ruminococcus flavefaciens, Bergeyella zoohelcum, Prevotella buccae and Listeria seeligeri. The total guide length is preferably 52-66 nucleotides. As known to those skilled in the art, the PAM motif of the type VI effector protein is variable and may include 3' non-G, 5' non-C and 3'NAN or NNA (BzCas13b) of LshCas13a, or none (RfCas13d). Cas13 is a prototype type VI effector protein.
[0029] The term "type III Cas protein", as used herein, refers to an RNA-targeting, multi-subunit CRISPR-associated complex that includes at least the Cas10 protein.
[0030] The term "Type IIIA Cas protein" as used herein refers to a Type III CRISPR / Cas protein complex targeted by RNA, which has non-specific DNase activity when bound to a target RNA molecule. For example, Type IIIA Cas proteins include Type IIIA Csm protein complexes from Staphylococcus thermophilus, Thermus thermophilus, and Staphylococcus epidermis.
[0031] The term "type III-B Cas protein" as used herein refers to a type III CRISPR-Cas protein complex targeted by RNA, which, in addition to type III-B Cas proteins from Thermus species, also has nonspecific DNase activity. The type III-B Cas complex consists of 6 to 7 separate proteins. For example, type III-B Cas proteins include type III-B Cmr protein complexes from Pyrococcus furiosus, Thermus thermophilus, and Sulfolobus solfataricus.
[0032] As used herein, the terms "quenched, quencher and quenching" refer to the process of reducing the signal intensity, preferably fluorescence intensity, of a given substance. Fluorescence quenching is a physicochemical process that absorbs light emitted by a fluorescent molecule. Fluorescence quenching can be used as an indicator in nucleic acid diagnostics, where a fluorophore and a quencher molecule are attached to the ends of a single-stranded nucleic acid molecule and are close to each other. When the nucleic acid molecule hybridizes with its target, or is cleaved by a nuclease, the fluorophore-quencher complex is pulled apart, allowing the fluorophore to produce light.
[0033] The term "dark quencher," as used herein, refers to a quencher that absorbs excitation energy from a fluorophore and dissipates the energy as heat. Thus, the dark quencher itself does not emit light. Dark quenchers are used in molecular biology together with fluorescent molecules.
[0034] As used herein, the term "cyclic oligoadenylate (cOA)" refers to a cyclic structure comprising 3-6 molecules of adenosine monophosphate (AMP). The formation of cOA is catalyzed by the cyclase domain of Cas10, which is part of the type III CRISPR / Cas effector system.
[0035] As used herein, the term "PPi" or pyrophosphate refers to a salt or ester of pyrophosphate. Other names include diphosphate and dipolyphosphate.
[0036] As used herein, the term "inorganic pyrophosphatase" or inorganic diphosphatase refers to an enzyme that catalyzes the conversion of one pyrophosphate ion into two phosphate ions. The enzyme belongs to the EC 3.6.1.1 enzyme class.
[0037] As used herein, the term "cOA-dependent effector protein" refers to a protein whose activity depends on the amount of cOA. Examples are ribonucleases (e.g., endoribonucleases) that use HEPN (higher eukaryotes and prokaryotes, nucleotide binding) active sites to non-specifically degrade RNA. These nucleases are activated by binding to one or more cOA molecules using their CRISPR-associated Rossmann fold (CARF) domains. Examples of such non-specific effector endoribonucleases are the Cas accessory proteins Csx1 of Pyrococcus furiosus and Csm6 of Mycobacterium tuberculosis.
[0038] As used herein, the term "non-naturally occurring protein" refers to a protein having an amino acid sequence and / or post-translational modification pattern that is different from that of the protein in the natural state. For example, a non-naturally occurring protein may have one or more amino acid substitutions, deletions, or insertions at the N-terminus, C-terminus, and / or between the N-terminus and the C-terminus of the protein. A "non-naturally occurring" protein may have an amino acid sequence that is different from a naturally occurring amino acid sequence but is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% identical to a naturally occurring amino acid sequence. In some cases, a non-naturally occurring protein, if produced by a different (e.g., bacterial) cell, may contain an N-terminal methionine or may lack one or more post-translational modifications (e.g., glycosylation, phosphorylation, etc.). In addition, a non-naturally occurring protein is a tagged protein that includes one or more specific tags through genetic engineering. Such tags include, but are not limited to, c-myc domains, hemagglutinin tags, maltose binding protein, glutathione-S-transferase, FLAG tag peptides, biotin acceptor peptides, streptavidin binding peptides and calmodulin binding peptides, such as those shown in Chatterjee, 2006 (Chatterjee, 2006 Cur Opin Biotech 17: 53-358).
[0039] As used herein, the term "non-naturally occurring nucleic acid" refers to a nucleic acid that contains: (1) a nucleotide sequence that differs from a nucleic acid found in nature; (2) one or more non-naturally occurring nucleotide monomers; and / or (3) one or more other modifications, such as an added label or other moiety.
[0040] The term "non-naturally occurring composition" refers to a composition that includes: (1) a combination of components that are not naturally associated, for example, because they are located in different locations, different cells, or different cellular compartments; (2) a combination of components with relative concentrations not found in nature; (3) a combination of components that lack a substance normally associated with a natural component; (4) a combination of components in a form not found in nature, for example, dried, lyophilized, crystalline, aqueous; and / or (5) a combination that contains components that do not occur in nature. For example, a formulation may contain a non-naturally occurring buffer, detergent, dye, solvent, or preservative. The composition can be in any form, for example, aqueous or lyophilized, and can be in any state, for example, frozen or aqueous.
[0041] As used herein, the term "primer" refers to an oligonucleotide preferably having a length of 15-50 nucleotides, which can effectively anneal to a template nucleic acid molecule and initiate transcription (including reverse transcription), or replicate the template nucleic acid molecule by a polymerase. The oligonucleotide may include deoxyribonucleotides, ribonucleotides, or a combination or variant thereof. The variant includes synthetic oligonucleotide analogs, such as phosphorothioates, phosphotriesters, 2-alkylated phosphorothioates and phosphoramide analogs, analogs with modifications at the 2'-position of the nucleoside sugar ring, such as 2'-fluoro, O-methyl or methoxyethyl, peptide nucleic acids, bridged nucleic acids, and / or locked nucleic acid molecules.
[0042] PhiFa_44 protein
[0043] Currently, there is no commercially available DNA-dependent RNA polymerase that can remain active at 65°C for more than 5 minutes. In order to find a thermostable DNA-dependent RNA polymerase, phages that may infect thermophilic bacteria, such as Thermus thermophilus, were analyzed. Bacteriophage phiFa (GenBank: MH673672.2; Taxonomy ID: 1400796) was identified as a candidate phage. PhiFa is an unclassified Oshima virus belonging to the Siphoviridae phage with a long and non-retractable tail. PhiFa encodes a hypothetical protein "phiFa_44" predicted to be an "RNA polymerase" (GenBank: QKE11339.1; SEQ ID NO: 1).
[0044] BlastP search identified a hypothetical protein WP_164703602.1 from Escherichia coli, which had a relatively high identity of 56.79% over about 90% of the length of the phiFa_44 protein. However, upon closer inspection, WP_164703602.1 appeared to be a contaminant in the sequencing analysis because it was not possible to align it with the E. coli genome. In addition, the coding sequence was uploaded to the database as a separate contig. The true origin of WP_164703602.1 is unclear. It was found that phFa_44 had no homology with the phage-derived RNA polymerases SP6, T3 and T7.
[0045] A further aligned sequence was a hypothetical protein from Planctomycetes bacterium (MBI5851759.1), which scored about 30% over 56% of the length of the phiFa_44 protein. The final aligned sequence was also a hypothetical protein from Escherichia coli (WP_206306715.1), which scored about 47% over only 10% of the length of the phiFa_44 protein.
[0046] Using the amino acid sequence of PhiFa_44 to search the Pfam database (Mistry et al., 2021, NucleicAcids Res 49: D412-D419), only one result with a length of 257 amino acid residues was identified, with a score of only 0.019. This score is not significant. One result identified (RdRP; PF05183) belongs to the eukaryotic RNA-dependent RNA polymerase family. These proteins are involved in post-transcriptional gene silencing, and they are thought to amplify dsRNA templates.
[0047] Using the HHpred tool in the Teubingen toolkit (available at toolkit.tuebingen.mpg.de / ) to search, two sequences, 5FSW_C and 2J7N_B, were identified, which had very low sequence similarity (25.8% and 17.5%, respectively). These two identified proteins were predicted to be RNA-dependent RNA polymerases. Sequences with even lower sequence similarity (<8%) were identified as multi-subunit DNA-dependent RNA polymerases.
[0048] The insignificant scores for both types of RNA-dependent RNA polymerase and multi-subunit RNA polymerase were considered unlikely in the case of phiFa_44.
[0049] Structural analysis was performed in silico to gain more insight into the phiFa_44 protein. Preliminary results showed some similarity to the QDE1 RNA-dependent RNA polymerase, with the similarity being up to 22% in a region of only 207 amino acid residues. However, this domain resembles a magnesium (Mg) binding domain. The predicted 3D structure (data not shown) confirmed these similarities and indicated that amino acid residues D366, D368, and D370 are residues in phiFa_44 that may be responsible for Mg binding.
[0050] Given the lack of significant sequence similarity to known RNA polymerases (e.g., bacteriophage-derived RNA polymerases SP6, T3, and T7), phiFa_44 was not considered a potential thermostable RNA polymerase. However, the IVT experiments that were eventually performed (see Example 1) indicated that phiFa_44 may function as a thermostable RNA polymerase despite the low sequence identity.
[0051] The protein of the present invention having at least 50% sequence identity with SEQ ID NO: 1 can be expressed and purified from a suitable expression system.
[0052] Common expression systems for heterologous protein production include Escherichia coli, Bacillus spp., baculovirus, yeast, fungi, filamentous fungi or yeasts (e.g., Saccharomyces cerevisiae and Pichia pastoris), eukaryotic cells (e.g., Chinese hamster ovary cells (CHO), human embryonic kidney cells (HEK), and cells (Thermo Fisher Scientific, MA, USA), and plants. The expression efficiency of recombinant proteins in heterologous systems depends on many factors, including transcription and translation levels.
[0053] The protein according to the invention having at least 50% sequence identity to SEQ ID NO: 1 is preferably produced in prokaryotes, preferably in Escherichia coli (E. coli). The protein is preferably produced by cloning of proteins expressed in prokaryotes of interest, preferably in E. coli. The expression construct, preferably DNA, is preferably produced by recombinant technology, including the use of polymerases, restriction endonucleases and ligases, as known to those skilled in the art. Alternatively, the expression construct is provided by artificial gene synthesis, for example by synthesizing partially or completely overlapping oligonucleotides, or by a combination of organic chemistry and recombinant technology, as known to those skilled in the art.
[0054] As an alternative or supplement, the protein according to the present invention having at least 50% sequence identity with SEQ ID NO: 1 can be isolated from the thermophilic organism by expressing a tagged protein according to the present invention having at least 50% sequence identity with SEQ ID NO: 1 in the thermophilic organism and isolating the protein based on the tag.
[0055] The expression construct is preferably codon optimized to enhance the expression of the protein of the present invention having at least 50% sequence identity with SEQ ID NO: 1 in the prokaryotic cell of interest, preferably E. coli. Further optimization may include removal of cryptic splice sites, removal of cryptic poly A tails and / or removal of sequences that lead to unfavorable folding of mRNA. In addition, the expression construct preferably encodes a protein export signal for secreting the protein of the present invention having at least 50% sequence identity with SEQ ID NO: 1 from the cell into the periplasm of the prokaryotic organism, thereby enabling effective purification of the protein of the present invention having at least 50% sequence identity with SEQ ID NO: 1.
[0056] Methods for purifying proteins of the invention having at least 50% sequence identity to SEQ ID NO: 1 are known in the art and are generally based on chromatographic methods such as affinity chromatography and ion exchange chromatography to remove contaminants. In addition to contaminants, it may also be necessary to remove undesirable derivatives of the product itself, such as degradation products and aggregates. Berthold and Walter, 1994 (Berthold and Walter, 1994. Biologicals 22: 135-150) provide suitable purification process steps.
[0057] As an alternative or supplement, the recombinant protein of the present invention having at least 50% sequence identity with SEQ ID NO: 1 can be tagged with one or more specific tags by genetic engineering so that the protein is attached to a column with specificity for the tag, thereby being separated from impurities. The purified protein is then exchanged from the affinity column with an uncoupling agent. This method has been increasingly applied to purifying recombinant proteins. Traditional tags for proteins, such as histidine tags, can be used with affinity columns that specifically capture the tags (e.g., Ni-IDA columns for histidine tags) to separate the protein from other impurities. Uncoupling agents are then used to exchange proteins from the column based on specific tags (e.g., imidazole for histidine tags). Compared with traditional purification methods, this method is more specific.
[0058] Suitable other tags include c-myc domains, hemagglutinin tags, maltose binding protein, glutathione-S-transferase, FLAG tag peptides, biotin receptor peptides, streptavidin binding peptides and calmodulin binding peptides, as mentioned in Chatterjee, 2006 (Chatterjee, 2006, Cur Opin Biotech 17, 353-358). Methods for using these tags are known in the art and can be used to purify proteins of the present invention having at least 50% sequence identity with SEQ ID NO: 1.
[0059] Methods for expressing proteins in E. coli are known in the art and can be used to express and purify a protein of the present invention having at least 50% sequence identity to SEQ ID NO: 1.
[0060] Method for transcribing a nucleic acid template
[0061] The present invention provides a thermostable DNA-dependent RNA polymerase that can perform in vitro transcription reactions at elevated temperatures without losing catalytic activity. The high temperature may increase specific activity and may help to mitigate the secondary structure of the RNA molecules produced. In addition, the availability of thermostable RNA polymerases enables one-pot reactions involving nucleic acid detection strategies amplified at high temperatures, such as LAMP amplification and synthesis of RNA chains, particularly detection systems involving type III CRISPR-Cas systems.
[0062] The thermostable RNA polymerase of the present invention has at least 50% sequence identity with SEQ ID NO: 1, preferably at least 60% sequence identity with SEQ ID NO: 1, preferably at least 70% sequence identity, preferably at least 80% sequence identity, preferably at least 90% sequence identity, preferably at least 91% sequence identity, preferably at least 92% sequence identity, preferably at least 93% sequence identity, preferably at least 94% sequence identity, preferably at least 95% sequence identity, preferably at least 96% sequence identity, preferably at least 97% sequence identity, preferably at least 98% sequence identity, preferably at least 99% sequence identity, preferably at least 99.5% sequence identity. Having at least 99.5% sequence identity with SEQ ID NO: 1 means that there may be one amino acid residue difference between the thermostable RNA polymerase and SEQ ID NO: 1.
[0063] Suitable template nucleic acid molecules are or include deoxynucleoside nucleotides, and include single-stranded (ss) DNA molecules, double-stranded (ds) DNA molecules, or hybrid ss-ds molecules. It has been found that the thermostable RNA polymerases of the present invention can generally transcribe single-stranded or double-stranded DNA molecules into RNA molecules. In general, low transcription activity apparently does not require a specific promoter region. For example Figure 1 As shown, initiation of transcription from a ds DNA template by a thermostable RNA polymerase (e.g., phiFA_44) appears to occur stochastically, resulting in a ladder of RNA products.
[0064] It is further found that the thermostable RNA polymerase of the present invention (e.g., phiFA_44) specifically transcribes a single-stranded DNA molecule into an RNA molecule, wherein the template strand includes the consensus sequence GGGGCGG, preferably AGGGGCGG, more preferably TAGGGGCGG, more preferably TAGGGGGGGM, more preferably TAGGGGCGGMTA, which can serve as the phiFA_44 promoter sequence, wherein M represents C or A. Sequence CA GGGGCGG CAA, including the consensus sequence GGGGCGG, is present in the ssDNA template A used for the IVT reaction, e.g. Figure 4 The sequence CA GGGGCGG CAA can function as a promoter sequence, producing an RNA transcript of approximately 70 nucleotides, e.g. Figure 4 Related sequences may drive transcription from discrete transcription start sites, resulting in a more defined RNA product of approximately 300 nt, such as Figure 1 shown.
[0065] The in vitro transcription reaction involving the thermostable RNA polymerase of the present invention is carried out in a suitable buffer to keep the pH at an almost constant value. The buffer may include phosphate, borate, N-cyclohexyl-2-aminoethanesulfonic acid (CHES), tris(hydroxymethyl)aminomethane (Tris), 2-(N-morpholino)ethanesulfonic acid (MES), glycine, and / or [tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS). The preferred reaction pH of the RNA polymerase is between 6 and 10, preferably between 7 and 9, such as 7.2, 7.5, 7.8, 8.0, 8.1, 8.5. 8.6 or 8.8.
[0066] A preferred buffer for the transcription reaction is or comprises Tris, preferably 10-100 mM Tris. The Tris is preferably set at the desired pH by adding an acid (eg acetic acid and / or hydrogen chloride).
[0067] Suitable buffers for transcription reactions may further include one or more divalent metal ions, such as Mg 2+ or Mn 2+ The divalent metal ion may be provided in the form of its salt, such as magnesium chloride, magnesium sulfate and / or magnesium acetate. The concentration is preferably between 0.5 and 20 mM, such as between 1 and 10 mM, preferably about 2 mM, about 3 mM, about 5 mM or about 7 mM.
[0068] Additional components of the buffer may include: potassium ions, such as potassium chloride; other salts, such as ammonium sulfate; and / or betaine, ethylene glycol, 1,2-propylene glycol and / or spermidine, as components known in the art to enhance transcription of template nucleic acid molecules, such as 2-10% DMSO or 2-10% glycerol (Cheng et al., 1994, Proc Natl Acad Sci 91:5695-5699).
[0069] Preferably, additional components are included in the reaction buffer to stabilize enzyme activity, including gelatin, albumin, a reducing agent (e.g., one or more of β-mercaptoethanol, dithiothreitol (DTT) and / or tris(2-carboxyethyl)phosphine (TCEP)), and / or a mild detergent (e.g., TWEEN 20 or Triton-X100).
[0070] The transcription reaction is carried out in the presence of ribonucleotides (NTPs), which include a nucleobase and a ribose group coupled to a triphosphate group. The nucleobases include adenine, guanine, cytosine, uracil, and any modifications thereof. The term ribonucleotide includes analogs of the reference ribonucleotide, such as fluorescent molecules, such as 1,3-diaza-2-oxophenothiazine-ribose-5'-triphosphate (tCTP), and / or other analogs, such as inosine, xanthine, N4-hydroxycytosine, N4-methoxycytosine, and 6H,8H-3,4-dihydropyrimidine [4,5-c] [1,2] oxazin-7-one (Suzuki et al., 2005, Nucleic Acids Symp Series 49: 97-98).
[0071] The transcription reaction is carried out at a temperature between 30°C and 80°C, preferably between 45°C and 75°C, for example between 50°C and 70°C, including 55°C, 60°C, 65°C.
[0072] The transcription reaction is preferably carried out in the presence of 10-50 mM (preferably 20 mM) Tris-HCl pH 8.8, 100-1000 nanoM (nM) (preferably about 500 nM) of a thermostable RNA polymerase of the present invention, 1-5 mM (preferably about 2.5 mM) of an NTP mixture (NEB #N0466S), 1-10 mM (preferably about 2 mM) of MgCl, 10-250 mM (preferably about 50 mM) of NaCl and a DNA template, preferably 1-100 ng (e.g., about 25 ng) of a dsDNA template, at a temperature of 45°C-75°C, e.g., between 50°C and 70°C, including 55°C, 60°C and 65°C, in a total volume of 20 microliters.
[0073] The IVT reaction is carried out for a suitable time to transcribe the DNA template, preferably the double-stranded DNA template. The amount of time is preferably 0.01 to 1 hour, more preferably 0.1 to 0.5 hours, and more preferably 0.2 to 0.4 hours.
[0074] Diagnostic tests
[0075] The method of the present invention enables the detection of specific nucleic acid sequences, which can be used in particular for human healthcare and veterinary diagnosis. For this purpose, nucleic acid material including DNA and / or RNA is preferably isolated from the sample. For this purpose, the nucleic acid material can be purified using, for example, a combination of physical and chemical methods. Preferably, commercially available nucleic acid isolation systems are used, such as or Nucleic Acid Extraction System (bioMérieux, Marcy l'Etoile, France) or MagNA Pure 96 System (Roche Diagnostics, Almere, The Netherlands).
[0076] The sample may include a biological fluid, such as saliva, an upper respiratory tract sample (e.g., a nasopharyngeal swab), a lower respiratory tract sample (e.g., sputum), nasopharyngeal secretions, oropharyngeal secretions, sweat, urine, feces, or blood. The term "blood" includes plasma and serum, wherein plasma is prepared by, for example, removing red blood cells and white blood cells by centrifugation, and serum is prepared by forming a blood clot and removing the blood clot using, for example, a centrifuge. The methods and compositions for separating nucleic acid materials from biological fluids, particularly swabs, preferably use aqueous solvents rather than organic solvents and chaotropic salts.
[0077] To this end, RNA can be isolated from the sample by any technique known in the art, including but not limited to suitable commercial RNA isolation kits, such as Trizol (Invitrogen; Carlsbad, California), (Applied Biosystems / Ambion, Austin, Tx), (Qiagen, Venlo, The Netherlands), Agilent Total RNA Isolation Lits (Agilent; Santa Clara, California), RNA- (Tel-Test. Friendswood, Texas), RNeasy mini kit (Qiagen, Venlo, The Netherlands) and Maxwell TM16 Total RNA Purification Kit (Promega; Madison, Wisconsin).
[0078] The isolated RNA is preferably reverse transcribed into single-stranded or double-stranded complementary DNA (cDNA) by means of an RNA-dependent DNA polymerase using methods known to those skilled in the art. Reverse transcription can be initiated by universal primers, such as random hexamers or nonamers, or by one or more specific primers, such as virus-specific or even gene-specific primers.
[0079] DNA, including genomic DNA, can be isolated from a sample by any technique known in the art, including, but not limited to, suitable commercial DNA isolation kits, such as the Quick-DNA Viral Kit (Zymo Research; Irvine, CA), NucleoSpin Dx Viral (Macherey-Nagel, Düren, Germany), QIAamp DNA Blood Mini Kit (Qiagen, Venlo, The Netherlands), and Viral DNA / RNA Kit (Transgen Biotech, Beijing, China).
[0080] The obtained RNA, DNA or cDNA can be directly used in the diagnostic assay based on CRISPR / Cas effector protein of the present invention, but preferably amplified before detection to improve the detection level. Amplification can be performed by any suitable amplification system, for example, including ligase chain reaction (LCR), isothermal ribonucleic acid amplification system such as nucleic acid sequence-based amplification (NASBA), cleavage-based RNA signal amplification (Zhao et al., 2013, Nature Comm 4: 1493), transcription-mediated amplification, strand displacement amplification and polymerase chain reaction (PCR).
[0081] Preferred amplification reactions are single tube isothermal reactions, such as NASBA, loop-mediated isothermal amplification (LAMP), helicase-dependent amplification (HAD), rolling circle amplification (RCA), multiple displacement amplification (MDA), recombinase polymerase amplification (RPA) reaction and nicking enzyme amplification reaction (NEAR). Preferred single tube isothermal reactions are loop-mediated isothermal amplification (LAMP) or recombinase polymerase amplification (RPA) reactions.
[0082] LAMP typically uses six primers to recognize different target sequences on the template strand. Four of these primers are "inner primers" (LF, LB, FIP, and BIP), which are designed to synthesize new DNA strands. The outer primers (F3 and B3) anneal to the template strands and also produce new DNA. These primers are accompanied by DNA polymerase, which facilitates strand displacement and releases the newly formed DNA strands. Under isothermal conditions of 60°C to 65°C, this amplification occurs in less than 1 hour, for example, less than 20 minutes.
[0083] The RPA process (TwistDx Ltd., Cambridge, UK) uses a recombinase, a single-stranded DNA binding protein (SSB) and a strand displacement polymerase, preferably supplemented with a reverse transcriptase, more preferably supplemented with a reverse transcriptase and a DNA-dependent RNA polymerase, such as T7 polymerase. The amplification is performed under isothermal conditions at 37°C to 42°C in less than 1 hour.
[0084] The thermostable RNA polymerase according to the present invention can replace DNA-dependent RNA polymerase in amplification reactions such as NASBA, cleavage-based RNA signal amplification (Zhao et al., 2013, Nature Comm 4: 1493), transcription-mediated amplification or RPA, thereby allowing higher temperatures to be used in the amplification reaction.
[0085] CRISPR / Cas-based detection system
[0086] The thermostable RNA polymerase of the present invention can be further used in a clustered regularly interspaced short palindromic repeats (CRISPR) nucleic acid detection system, which includes a CRISPR-associated effector protein (Cas) and at least one CRISPR RNA (crRNA) that binds to a target nucleic acid molecule.
[0087] The CRISPR / Cas based detection system is preferably provided in the form of a sensing device, or "biosensor", comprising the CRISPR based nucleic acid system of the present invention. The signal generated when the CRISPR based nucleic acid system interacts with a nucleic acid molecule complementary to crRNA, such as a colorimetric, fluorescent, fluorescent or bioluminescent signal, can be coupled to a transducer to allow the signal to be quantified. The signal can be directly visualized, or alternatively or additionally, the signal can be converted into a measurable electrical parameter, such as a current or voltage, by means of a suitable transducer.
[0088] The binding of crRNA to the target sequence can activate the Cas effector protein. The activation of the Cas effector protein can be detected by collateral cleavage of reporter molecules mediated by, for example, Cas12, Cas13, and Cas14 and / or by the production of cyclic oligoadenylate (cOA) catalyzed by the cyclase domain of Cas10.
[0089] Crispr / Cas 1-type systems utilize multi-protein effector complexes (Koonin et al., 2017, Curr Opin Microbiol 37: 67-78), and include type I systems, type III (e.g., Cas10), and type IV systems. Crispr / Cas 2-type systems utilize single protein effectors and include type II CRISPR systems (e.g., Cas9), type V systems (e.g., Cas12 (also known as cpf1) and Cas 14 (Harrington et al., 2019, Science 362: 839-842)), and type VI systems (e.g., Cas13 (Makarova et al., 2017, Cell 168: 328-328)).
[0090] Binding of crRNA to its target nucleic acid sequence activates the collateral, trans-acting nuclease activity of type V or type VI CRISPR / Cas effector proteins. This collateral, trans-acting nuclease activity enables the use of single-stranded "reporter" molecules to score the activation of type V or type VI CRISPR / Cas effector proteins.
[0091] The reporter molecule of the activated V-type or VI-type Cas is preferably a single-stranded nucleic acid molecule of at least 9 nucleotides, and the cleavage of the activated V-type or VI-type Cas is detectable. The single-stranded nucleic acid molecule preferably includes 9 to 50 nucleotides, more preferably 10 to 25 nucleotides or even 11 to 20 nucleotides, such as 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides or 19 nucleotides. The optimal length of the reporter molecule is about 12 nucleotides.
[0092] The reporter molecule includes a single-stranded DNA for detecting an activated Cas12 or Cas14 effector protein, or includes a single-stranded RNA for detecting an activated Cas13 effector protein. The reporter molecule may include a deoxyribonucleotide or a ribonucleotide analog, such as a ribonucleotide and a deoxyribonucleotide based on inosine, uridine, xanthine, hypoxanthine, 2,6-diaminopurine, and 6,8-diaminopurine.
[0093] Detection of reporter cleavage can be performed by any method known in the art. For example, detection can be performed directly by mass spectrometry, such as ultra-high performance liquid chromatography (UHPLC) coupled with tandem mass spectrometry (LC-MS / MS) in electrospray positive ion mode. LC-MS / MS analysis can be performed, for example, using a high-end UHPLC chromatography system coupled with a triple quadrupole mass spectrometer. Detection can be further performed by liquid-liquid phase separation (LLPS; Spoelstra et al., 2018, BioRXiv, CSHL (doi.org / 10.1101 / 471482)), or by colorimetric, fluorescence, fluorescent or bioluminescent detection methods known to those skilled in the art.
[0094] Suitable reporter molecules are single-stranded RNA (Cas13) or DNA (Cas12 and Cas14) molecules, one end of which is labeled with a fluorescent marker and the other end is labeled with a quencher. The close proximity of the reporter molecule to the quencher prevents the detection of its fluorescence. After activating the side-cutting trans-acting nuclease activity of type V or type VI CRISPR / Cas effector proteins, the cleavage of the substrate destroys the proximity of the reporter molecule-quencher, thereby allowing unquenched fluorescence emission, which can be detected after laser excitation.
[0095] Preferred fluorescent labels can be selected from: Atto425 (ATTO-TEC GmbH, Siegen, Germany), Atto647N (ATTO-TEC GmbH, Siegen, Germany), YakimaYellow (Epoch Biosciences Inc, Bothell, WA, USA), Cal610 (BioSearch Technologies, Petaluma, CA, USA), Cal635 (BioSearch Technologies, Petaluma, CA, USA), FAM (Thermo Fisher Scientific Inc., Waltham, MA USA), TET (Thermo Fisher Scientific Inc., Waltham, MA USA), HEX (ThermoFisher Scientific Inc., Waltham, MA USA), cyano dyes such as Cy5, Cy5.5, Cy3, Cy3.5, Cy7 (Thermo Fisher Scientific Inc., Waltham, MA USA), Alexa dyes (Thermo Fisher Scientific Inc., Waltham, MA USA, Tamra (Thermo Fisher Scientific Inc., Waltham, MA USA), ROX (Thermo Fisher Scientific Inc., Waltham, MA USA), JOE (Thermo Fisher Scientific Inc., Waltham, MA USA), fluorescein isothiocyanate (FITC, Thermo Fisher Scientific Inc., Waltham, MA USA), Yakima (YY; Epoch Biosciences, Bothell, Washington) and tetramethylrhodamine (TRITC, Thermo Fisher Scientific Inc., Waltham, MA USA). The substrate is preferably labeled at the 5' end with a detectable label, preferably a fluorescent label.
[0096] Quenchers, such as tetramethylrhodamine TAMRA, a dihydrocyclopyrroloindole tripeptide minor groove binder, are known in the art. Preferred quenchers include Black Hole -1 (BHQ1) and BHQ2 (Biosearch Technologies, Petaluma, CA, USA). BHQ1 dark quencher has strong absorption in the range of 480nm to 580nm, which quenches fluorophores that emit fluorescence in this range, such as FAM, TET, CAL Gold 540, JOE, HEX, CAL FluorOrange560 and 570 dye. BHQ2 dark quencher has strong absorption in the range of 599nm to 670nm, which quenches fluorophores that fluoresce in this range, e.g. 570, TAMRA, CAL Red 590, CAL FluorRed610, ROX, CAL FluorRed 635, The dyes used are Quasar 650, Quasar 670, and Quasar 705. BHQ1 and BHQ2 can quench fluorescence through both FRET and static quenching mechanisms.
[0097] Further preferred reporter molecules allow detection in a lateral flow assay (LFA). The principle of LFA is to fix the reaction product, in this case the unreacted reporter molecule, to a first point called the control line, and to fix the cleaved reporter molecule to a second point called the test line. LFA is generally composed of a nitrocellulose membrane, a sample pad, a conjugate pad, a hygroscopic or absorbent pad, and a liner (Jauset-Rubio et al., 2016, Sci Rep 6: 37732). Nitrocellulose membranes are the most commonly used because they facilitate carriers that can be used for both reaction and detection, wherein the captured biomolecules (e.g., antibodies) are deposited on the nitrocellulose by a combination of electrostatic interactions, hydrogen bonds, and / or hydrophobic interactions to form test and control lines (Jauset-Rubio et al., 2016, Sci Rep 6: 37732).
[0098] Alternatively, the combination of crRNA and its target nucleic acid sequence activates the cyclase domain (eg, Cas10) of the type III effector system. The ribonucleic acid detection system based on Cas10 is preferably derived from thermophilic organisms, such as Pyrococcus furiosus, Sulfolobus solfataricus, or Thermus thermophilus. For this system, the target DNA molecule needs to be transcribed into a target RNA molecule, such as by the thermostable RNA polymerase of the present invention, so as to allow the transcription reaction to be performed at a higher temperature. Further advantages are that the three steps of amplification, transcription, and detection can be performed at high temperatures (eg, about 65 ° C), so that all steps are suitable for one-pot reactions.
[0099] A further advantage of the CRISPR / Cas-based RNA detection system from thermophilic organisms is that the detection can be performed at high temperatures, such as between 40°C and 80°C, preferably between 50°C and 70°C, such as between 55°C and 65°C, preferably about 65°C. Incubation at this temperature can accelerate the cOA synthesis reaction compared to incubation at lower temperatures. In addition, the high temperature may inactivate nucleases (e.g., DNase or RNase) or proteases present in the sample.
[0100] Furthermore, compared to CRISPR / Cas-based RNA detection systems from mesophiles, CRISPR / Cas-based RNA detection systems from thermophiles have the advantage of providing increased stability to the system, for example, it can be stored for a longer period of time.
[0101] Recent studies have shown that the presence of cOA leads to a substantial increase in RNase activity of Csm6 or Csx1 family members. These proteins are often encoded in type III loci but are not directly associated with ribonucleoprotein complexes. Instead, recognition of invading RNA transcripts may result in degradation of the target RNA by Cas7, degradation of nonspecific DNA by class I and type IIIA Cas10, and production of cOA, leading to activation of Csm6 or Csx1, resulting in para-cleavage of other nearby single-stranded RNA molecules.
[0102] Methods for directly determining cOA levels preferably include methods for determining pyrophosphate or PPi levels. The formation of pyrophosphate is coupled to the formation of cOA by CRISPR / Cas-associated proteins (e.g., Cas10) with ATP. The formation of cOA consisting of 3-6 AMP units allows the simultaneous formation of 3-6 PPi molecules.
[0103] Alternatively, the detection system of the present invention may include an inorganic pyrophosphatase, which may cause the decomposition of PPi, and each PPi molecule forms two inorganic phosphate molecules. Thus, by determining the level of inorganic phosphate, the number of detectable molecules can be expanded from 1 molecule of cOA to 6-12 molecules of Pi.
[0104] Preferred inorganic pyrophosphatases are enzymes that are active at the same or similar temperature as the RNA detection system based on type III CRISPR / cas. In addition, preferably, the inorganic pyrophosphatase is active under the same or similar conditions as the RNA detection system based on type III CRISPR / Cas (including at the same or similar pH and the same or similar salt concentration). For example, if the RNA detection system based on type III CRISPR / Cas has optimal activity at 50°C, it is preferred that the inorganic pyrophosphatase is active at that temperature. Preferably, the activity of the inorganic pyrophosphatase at 50°C is such that substantially all PPi molecules are decomposed into inorganic phosphate molecules. The decomposition is preferably instantaneous. Similarly, at a selected pH and salt concentration, the activity of the inorganic pyrophosphatase is such that substantially all PPi molecules are decomposed into inorganic phosphate / ester molecules. The decomposition is preferably instantaneous.
[0105] Preferred inorganic pyrophosphatases are from thermophilic organisms, such as Pyrococcus furiosus, Sulfolobus solfataricus and Thermus thermophilus, allowing simultaneous isothermal detection. In this case, the level of cOA can be determined directly by determining the level of Pi.
[0106] PPi and Pi can be detected using methods known in the art, including colorimetric, fluorescence, luminescence, or bioluminescence based assays.
[0107] Suitable methods for determining PPi levels include fluorescent and / or colorimetric pyrophosphate (PPi) assay kits (Biovision Inc., Milpitas, CA); Pyrophosphate Detection Kit (ThermoFisherScientific; Waltham, MA); Fluorescent Pyrophosphate Assay Kit (SigmaAldrich, Saint Louis, MO); and Luminescent PPiLight TM Assay (Lonza Group AG, Bazel, Switzerland).
[0108] Suitable methods for determining inorganic phosphate or Pi levels include the colorimetric PiColorLock TMAssay (Expedeon, Cambridge, UK); colorimetric Malachite phosphate assay kit (SigmaAldrich, Saint Louis, MO); fluorescent phosphate sensor (ThermoFisher Scientific; Waltham, MA); luminescent readout after conversion of ADP to ATP (US patent application US20140273036A); fluorescent chemical sensor (Meng et al., 2015, RSC Advances 5:53189-53197); photoluminescent graphene quantum dots bound to europium ions (Bai et al., 2013, Chemistry 19:3822-3826).
[0109] The methods and devices for the direct determination of cyclic oligoadenylic acid (cOA) levels preferably comprise at least one substrate and, if desired, an enzyme allowing at least one indicator detection method for PPi or Pi.
[0110] A preferred method is a colorimetric method, such as the Malachite Green Phosphate Assay Kit, which allows for rapid determination of PPi or Pi levels as a direct determination of cOA levels.
[0111] Methods for indirectly determining cOA levels preferably include methods for determining the activity of cOA-dependent non-specific effector nucleases, such as CRISPR accessory nuclease 1 (Can1) or Can2, and preferably methods for determining the activity of cOA-dependent non-specific effector ribonucleases, such as Csx1. To this end, the detection system according to any of the present invention preferably includes a cOA-dependent non-specific effector endoribonuclease, such as Csx1.
[0112] The cOA-dependent non-specific effector nuclease, preferably an endoribonuclease, is preferably an enzyme that is active at the same or similar temperature as the RNA detection system based on type III CRISPR / Cas. In addition, preferably, the cOA-dependent non-specific effector endoribonuclease is active under the same or similar conditions as the RNA detection system based on type III CRISPR / Cas (preferably including the same or similar pH and the same or similar salt concentration). For example, if the RNA detection system based on type III CRISPR / Cas has optimal activity at 65°C, it is preferred that the cOA-dependent non-specific effector endoribonuclease is active at this temperature. Preferably, the activity of the cOA-dependent non-specific effector endoribonuclease at 65°C causes the cOA-induced activity of the cOA-dependent non-specific effector endoribonuclease to cause the substrate of the cOA-dependent non-specific effector endoribonuclease to produce a detectable amount of reaction product. Similarly, at a selected pH and salt concentration, the activity of the cOA-dependent non-specific effector endoribonuclease is such that the cOA-induced activity of the cOA-dependent non-specific effector endoribonuclease results in a detectable amount of a reaction product from a substrate of the cOA-dependent non-specific effector endoribonuclease.
[0113] The substrate of the coA-dependent non-specific effector endoribonuclease is preferably an RNA molecule, and its cutting can be detected. Detection can be performed by any method known in the art. For example, detection can be performed directly by mass spectrometry, for example, ultra-high performance liquid chromatography (UHPLC) coupled to tandem mass spectrometry (LC-MS / MS) is performed in electrospray positive ion mode. LC-MS / MS analysis can be performed by using a high-end UHPLC chromatography system coupled to a triple quadrupole mass spectrometer.
[0114] Detection can be further performed by liquid-liquid phase separation (LLPS; Spoelstra et al., 2018, BioRXiv, CSHL (doi.org / 10.1101 / 471482).
[0115] The preferred substrate of the cOA-dependent nonspecific effector endoribonuclease is an RNA molecule with a fluorescent reporter molecule labeled at one end and a quencher labeled at the other end. The close proximity of the reporter molecule to the quencher prevents the detection of its fluorescence. The substrate is cut by activating the cOA-dependent nonspecific effector endoribonuclease, destroying the proximity of the reporter molecule-quencher, thereby allowing unquenched fluorescence emission, which can be detected after laser excitation. Therefore, due to the removal of the quencher of the substrate cutting and quenching the fluorescent reporter molecule, the increase of the cOA-dependent nonspecific effector endoribonuclease activity causes a proportional increase in fluorescence.
[0116] Different from the activation of non-specific effector endoribonuclease, or in addition to it, the determination of target recognition level can also be carried out by determining the activation of non-specific effector DNA enzyme activity present in type IIIA CRISPR / Cas effector complex using a suitable substrate of the nuclease. The suitable substrate is preferably a DNA molecule labeled with a fluorescent marker at one end and a quencher at the other end. Examples of suitable fluorescent markers and quenchers are provided above. The close proximity of the reporter molecule to the quencher prevents the detection of its fluorescence. The substrate is cut by activating the cOA-dependent non-specific effector DNA enzyme, destroying the proximity of the reporter molecule-quencher, thereby allowing unquenched fluorescence emission, which can be detected after laser excitation. Due to the removal of the quencher of the cutting of the substrate and the quenching of the fluorescent reporter molecule, the activity of the cOA-dependent non-specific effector DNA enzyme increases, thus causing the fluorescence to increase proportionally. The use of activation of a non-specific effector endoribonuclease and activation of a non-specific effector DNA enzyme allows the presence or absence of two independent target RNA molecules to be determined in one single assay, provided that one of the two independent ribonucleoprotein complexes used specifically activates the non-specific effector DNA enzyme and the other specifically allows for indirect or direct determination of cOA levels. One skilled in the art will appreciate that, to this end, the fluorescent labels present on the substrate by activation of the cOA-dependent non-specific effector endoribonuclease and the non-specific effector DNA enzyme must be sufficiently different to allow the level of each activity to be determined as a measure for determining cOA levels.
[0117] Suitable commercial substrates are The Lab test kit v2 (ThermoFisher Scientific; Waltham, MA) was provided.
[0118] Preferred cOA-dependent non-specific effector endoribonucleases are from thermophilic organisms, such as Pyrococcus furiosus, Sulfolobus solfataricus, and Thermus thermophilus, allowing for simultaneous, isothermal detection of cOA-dependent non-specific effector endoribonuclease activity.
[0119] The method and device for indirectly determining the level of cyclic oligoadenylate (cOA) preferably comprises a cOA-dependent non-specific effector endoribonuclease and a substrate for the cOA-dependent non-specific effector endoribonuclease.
[0120] For purposes of clarity and concise description, features are described herein as part of the same or separate embodiments, however it should be understood that the scope of the invention may include embodiments having a combination of all or some of the described features.
[0121] 5 Examples
[0122] Example 1
[0123] Materials and methods
[0124] Protein purification
[0125] The protein nucleotide sequence under study was codon-optimized for Escherichia coli (see Table 1) and placed in a bicistronic expression plasmid containing a Strep-tag at the N-terminus (Nieuwkoop et al., 2019, Microbiol Biotechnol 12: 173-179). The expression plasmid was transformed into Escherichia coli strain Bl21 (DE3) and grown at 37°C with the required culture (2-12 L) until an OD600 of about 0.6 was reached. The culture was placed on ice for 1 hour, after which IPTG was added to a final concentration of 0.5 mM. The culture was then incubated at 20°C for about 16 hours (overnight). The cells were harvested and lysed by ultrasound in buffer A (100 mM Tris-HCl, 150 mM NaCl, pH 8), followed by rotation at 30.000 g for 45 minutes. The clarified lysate was filtered (0.45 microns) and purified using a StrepTrap FPLC column. The protein of interest was eluted with buffer B (100 mM Tris-HCl, 150 mM NaCl and 2.5 mM desthiobiotin, pH 8.0). Subsequently, the heparin purification step was performed using buffer C (100 mM Tris-HCl, 125 mM NaCl, pH 8) as a binding and washing buffer. Gradient elution was then performed using buffer D (100 mM Tris-HCl, 1 M NaCl, pH 8). Finally, size exclusion chromatography was performed in buffer A using a Superdex 200 Enhanced 10 / 300 GL column (Cytiva; Marlborough, MA).
[0126] IVT assay
[0127] IVT assays were performed using a base composition of 1× isothermal amplification buffer (NEB#B0537S), 250 nM phiFa_44, 1.875 mM rNTP / dNTP, 80 ng dsDNA template in a total volume of 20 microliters. The reactions were incubated at 65°C for 1 h, followed by incubation at 95°C for 10 min. Subsequently, 2.3 microliters of DNaseI buffer and 1 microliter of DNaseI enzyme (NEB#B0303 and #M0303, respectively) were added, and the reactions were incubated at 37°C for 30 min. The reaction mixtures were separated on a 10% UREA-PAGE gel and stained with SybrGold (Thermo#S11494).
[0128] Temperature and NaCl concentration optimization analysis
[0129] IVT assays were performed using a base composition of 20 mM Tris-HCl pH 8.8, 500 nM phiFa_44, 2.5 mM rNTP mix (NEB #N0466S), 2 mM MgCl, 50 mM NaCl, and 25 ng of dsDNA template in a total volume of 20 microliters. To determine the optimal NaCl concentration, the reaction mixtures were identical, only the NaCl concentration was varied. After incubation of the reactions at 65°C for 1 h, the reactions were cleaned up using the Zymo RNA Cleanup and Concentration Kit (Zymo #R1017). DNase treatment was then performed at 37°C for 1 h in a total reaction volume of 20 microliters (NEB #M0303S). The reaction mixtures were separated on a 10% UREA-PAGE gel and stained with SybrGold (Thermo #S11494).
[0130] ScopeDx assay
[0131] The ScopeDx assay mixture consisted of the following items: 1×Warmstart LAMP Mastermix (NEB#E1700), primers (FIP / BIP 1.6mM, F3 / B3 0.2mM, LoopF / LoopB 0.4mM), 62.5nM reconstructed TtCmr46 complex containing E gene crRNA (Steens et al., 2021, Nature Comm 12: 1-12), 1mM TtHB144 (Steens et al., 2021, Nature Comm 12: 1-12), 250nM rNTP mix (NEB#N0466), 500nM RNaseAlert V2 (Thermo#4479769) and 175nM phiFa_44. Different amounts of Twist SARS-CoV-2 synthetic genome MN908947.3 were added to the reaction mixture and incubated at 65°C while time points were measured on the FAM channel.
[0132] result
[0133] In vitro transcription assay
[0134] To determine whether dsDNA is a suitable template, a segment from the phiFa phage genome was extracted as a synthetic gene. The region containing the end of phiFa-45, the intergenic region, and the start of the phiFa-44 gene was selected (see Table 1). Figure 1 An in vitro transcription assay designed to determine whether a polymerase uses rNTPs or dNTPs as a substrate and whether DNA or RNA is produced is performed as shown.
[0135] From these results, we concluded that the template used was dsDNA, which together with the rNTP substrate was used to generate the RNA product (see Figure 1 10-13 lanes).
[0136] Temperature and NaCl concentration optimization analysis
[0137] IVT assays were performed using various NaCl concentrations and temperatures, indicating that the optimal NaCl concentration was between 25 and 200 mM and the optimal temperature ranged from 45 °C to 75 °C.
[0138] One Pot ScopeDx
[0139] In the ScopeDx 1.0 tool, as described in Steens et al., 2021, Nature Comm 12: 1-12, we were able to link LAMP pre-amplification (65°C) to CRISPR readout (65°C). However, because the commercial Hi-T7 RNA polymerase used was incompatible with extended incubation at 65°C, a step had to be added to the protocol. LAMP pre-amplification was first performed at 65°C for 30 min, and then the Hi-T7+CRISPR mix was added and incubated at 65°C for another 10-20 min. In this way, the Hi-T7 RNA polymerase (which has a limited duration of activity) is able to transcribe the dsDNA produced by the pre-amplification into RNA, which can then be detected by the CRISPR system.
[0140] Since phiFa_44 is able to transcribe DNA into RNA at 65°C, we decided to test it in the one-pot ScopeDx2.0 assay. The assay was performed as a single step at 65°C on a synthetic SARS-CoV-2 RNA genome ( Figure 2 ). Using this new assay, a detection limit of 200 copies was achieved in less than 25 minutes, demonstrating a dramatic improvement in time-to-signal. Furthermore, the fact that it is now a one-step protocol greatly reduces the risk of contamination, which could occur if the tubes needed to be opened between steps, and improves high-throughput and automation capabilities.
[0141] Structural analysis performed on computers
[0142] In silico structural analysis was performed to gain more insight into the phiFa_44 protein. Preliminary results suggest similarities to the QDE1 polymerase-like enzyme. The dimerization behavior of QDE1 may also be similar to that of phiFa_44. Currently, based on amino acid alignments (see Figure 4 ), allowing the identification of the magnesium-binding domain. The predicted 3D structure confirmed these similarities and indicated that D366, D368, and D370 are the residues responsible for Mg binding in phiFa_44.
[0143] Example 2
[0144] Materials and methods
[0145] IVT assay
[0146] IVT assays were performed in a total volume of 20 microliters using a base composition of 1× Isothermal Amplification Buffer (NEB #B0537S), 250 nM PhiFa-44, 1.875 mM rNTP / dNTP, 80 ng double-stranded (ds) DNA template or 100 nM (final concentration) single-stranded (ss) DNA oligonucleotides. The reactions were incubated at 65°C for 1 h, followed by incubation at 95°C for 10 min. 2.3 microliters of DNaseI buffer and 1 microliter of DNaseI enzyme (NEB #B0303, #M0303) were added, and the reactions were incubated at 37°C for 30 min. The reaction mixtures were separated on a 10% UREA-PAGE gel and stained with SybrGold (Thermo #S11494).
[0147] ssDNA template A is 5'-GCGCTCCAAAAGCAGGGGCGGCAAGTCCAGTCT CCAGACTTGCCGCCGAGTGTACCTGCTTGCTACAGCCCTAATTATACCACAAACGCC3'.
[0148] ssDNA template B is 5'-GGCGTTTGTGGTATAATTAGGGCTGTAGCAAGC AGGTACACTC GGCGGCAAGTCTGGAGACTGGACTTGCCGCCCCTGCTTTTGGAGCGC3.
[0149] The dsDNA template consists of annealed ssDNA template A and ssDNA template B.
[0150] result
[0151] PhiFa IVT ssDNA Template
[0152] The IVT reaction was performed using a 90 nt ssDNA template and a template B complementary to template A (see Figure 4 ). This region of the PhiFa genome was selected because it contains a potential motif of interest. It can be clearly seen from the results that ssDNA template A produced a clear ssRNA transcript of about 75-80 nt, while ssDNA template B did not provide a clear transcript. This result indicates that ssDNA template A contains a motif of interest that is preferred by the PhiFa44 polymerase.
[0153] Very little is known about how phage PhiFA expresses its genes. Normally, phages use host RNA polymerases to express them, but since phage PhiFA encodes its own RNA polymerase, it is reasonable to assume that (at least) some of its genes are expressed by this specific polymerase (encoded by the PhiFA_44 gene).
[0154] Example 3
[0155] Materials and methods
[0156] In vitro RNA transcription assay
[0157] PhiFa-44 was purified by labeling (His)-6 in 50mM NaCl, 100Mm Tris-HCl pH 8.0, and the single-stranded DNA template (50nt; SEQ ID NO: 12) was 5' labeled with Cy3 fluorescent dye. The ssDNA template was purified from denaturing PAGE using the "ZR Small-RNA PAGE Recovery Kit" (ZymoResearch, R1070). In vitro RNA transcription assays were performed in PhiFa-44 reaction buffer (35mM NaCl, 20mM Tris-HCl pH 8.8, 2mM MgCl2 and 25mM rNTP) and supplemented with Milli-Q to a final volume of 20μl. When needed, the ssDNA template and PhiFa-44 were added to the reaction mixture at final concentrations of 62μM and 1μM, respectively.
[0158] All reactions were incubated at 65°C for 2 h, and then RNA / DNA was cleaned up using the "RNA Clean Concentrator Kit (ZymoResearch, R1017). After adding RNase H (NEB, 5U / μl) to the selected purification samples, all reactions were incubated at 37°C for 30 min. To analyze the reaction products, 2X RNA loading dye (200mMTris-HCl pH 8.0, 30% glycerol, 900mM NaCl) was added to all incubation samples, and then they were loaded on a native 4-20% (w / v) gradient polyacrylamide gel. Fluorescent gel scanning (GE Amersham Typhoon) was used to visualize the gel. Cy3 filter (560-580nm) was used to display Cy3-labeled reaction products, while SYBR Gold staining and application of Cy2 filter (515-535nm) displayed all nucleic acids present on the gel.
[0159] result
[0160] like Figure 5As shown, in vitro transcription using PhiFa-44 and ssDNA as templates forms complementary RNA, which can be indicated by the shift of the ssDNA template band. When MgCl was not added and no incubation was performed (negative control), no shift was observed. Similarly, the addition of RNase H (an enzyme that cleaves RNA) to the RNA:DNA duplex abolished the shift of the ssDNA template band.
[0161] These results indicate that PhiFa-44 is able to transcribe single-stranded template DNA into RNA.
[0162]
[0163]
[0164]
Claims
1. A method comprising: Incubating the template nucleic acid molecule and a protein having at least 50% sequence identity to SEQ ID NO: 1 in the presence of rNTPs and a suitable buffer; and By carrying out the transcription reaction at a temperature between 30°C and 80°C, at least a portion of the template nucleic acid molecule is transcribed into an RNA molecule.
2. The method according to claim 1, wherein: The template nucleic acid molecule is a deoxyribonucleic acid (DNA) template molecule.
3. The method according to claim 1 or 2, wherein: The buffer includes 25 mM to 200 mM NaCl.
4. The method according to any one of claims 1 to 3, wherein: The transcription reaction is carried out at a temperature between 45°C and 75°C.
5. The method according to any one of claims 1 to 4, wherein: The template nucleic acid molecule is generated by a pre-amplification reaction.
6. The method according to any one of claims 1 to 5, wherein: The transcribed RNA molecules are further incubated with a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) protein-based nucleic acid detection system.
7. The method according to claim 6, wherein: The CRISPR-Cas nucleic acid detection system comprises: a) an effector complex comprising a type III Cas protein and at least one CRISPR RNA (crRNA) that binds to a target RNA molecule; b) Means for directly or indirectly determining the level of cyclic oligoadenylic acid (cOA).
8. The method according to claim 6 or 7, wherein: The preamplification reaction, transcription reaction and incubation with the nucleic acid detection system are all performed in a one-pot reaction.
9. A protein having at least 50% sequence identity to SEQ ID NO:
1.
10. The protein according to claim 9, comprising a suitable tag.
11. A nucleic acid molecule encoding the protein of claim 9 or 10.
12. The nucleic acid molecule of claim 11, which is codon-optimized to express the protein in a suitable host cell.
13. A host cell expressing the protein of claim 9 or 10.
14. Use of the protein according to claim 9 or 10 in performing a transcription reaction to transcribe at least part of a template nucleic acid molecule into an RNA molecule.
15. The use according to claim 14, wherein The transcription reaction is carried out at a temperature between 30°C and 80°C, preferably between 45°C and 75°C.
